Lauvao Lannery, Burgess Jason, O'Brien-Coon Devin, Rogers Tyson, Yevzlin Alex, Beaver Jason
Mana Vascular Clinic, Glendale, AZ, USA.
Surgical Specialists of Charlotte, Charlotte, NC, USA.
J Vasc Access. 2025 Sep;26(5):1520-1530. doi: 10.1177/11297298241287609. Epub 2024 Oct 6.
EchoSure is an automated point-of-care 3D ultrasound (3DUS) designed to be used by dialysis technicians without advanced ultrasound training. The EchoMark/EchoSure System is a two-part system comprised of a bioresorbable implant, EchoMark, and a diagnostic ultrasound imaging platform, EchoSure. EchoSure was designed to enable any healthcare personnel in a dialysis clinic setting to obtain non-invasive, direct measurements of flow and vessel parameters that are critical quantifications used in the assessment of AVF maturation and readiness for hemodialysis cannulation.
In this pilot feasibility study, we sought to explore whether use of an automated 3DUS could enable fistula assessment by non-experts and obtain measurement accuracy comparable to expert sonographer Duplex.
This was a 20 subject prospective multicenter trial conducted at four sites in the United States. All subjects had an EchoMark implanted under their AVF during the fistula creation procedure. Subjects were evaluated at 2-weeks post-op with EchoSure and Duplex, followed by monthly assessments until either the 4-month visit or until radiographic maturation was achieved, whichever was longer. Beyond monthly ultrasound assessments, clinical follow-up continued every 6 months between months 6 and 24.
Technical success of EchoMark implantation was demonstrated in 100% of subjects. Technical success of EchoSure was 99% across all scans. The mean percent difference in flow rate measurements between EchoSure and Duplex was -9.2% with a standard deviation of 38.1% compared to a mean percent difference of -15.7% with a standard deviation of 35.5% between Duplex measurements taken at the cannulation zone and brachial artery. Pearson correlation between EchoSure and Duplex was 0.708 versus 0.716 for the two Duplex measurements. Radiographic maturation was achieved in 70% of study subjects by 30 days and continued to rise to 90% through 90 days and 95% through 180 days after baseline.
This study demonstrates the feasibility and accuracy of an automated 3D ultrasound system for assessment of maturation at the dialysis bedside by non sonographers.
EchoSure是一款自动化的即时床旁三维超声(3DUS)设备,设计供未经高级超声培训的透析技术人员使用。EchoMark/EchoSure系统由两部分组成,包括一种可生物吸收的植入物EchoMark和一个诊断超声成像平台EchoSure。EchoSure旨在使透析诊所环境中的任何医护人员能够获得流量和血管参数的非侵入性直接测量值,这些关键量化指标用于评估动静脉内瘘(AVF)的成熟度以及进行血液透析插管的准备情况。
在这项初步可行性研究中,我们试图探讨使用自动化3DUS是否能让非专家人员进行瘘管评估,并获得与专业超声检查医师使用双功超声相当的测量准确性。
这是一项在美国四个地点进行的纳入20名受试者的前瞻性多中心试验。所有受试者在造瘘手术过程中于其AVF下方植入EchoMark。术后2周使用EchoSure和双功超声对受试者进行评估,随后每月评估一次,直至4个月随访或直至达到影像学成熟,以时间较长者为准。除每月超声评估外,在6至24个月期间每6个月进行一次临床随访。
100%的受试者EchoMark植入技术成功。所有扫描中EchoSure的技术成功率为99%。EchoSure与双功超声之间流速测量的平均百分比差异为 -9.2%,标准差为38.1%,而在插管区和肱动脉进行的双功超声测量之间的平均百分比差异为 -15.7%,标准差为35.5%。EchoSure与双功超声之间的Pearson相关性为0.708,而两次双功超声测量之间的相关性为0.716。70%的研究受试者在基线后30天达到影像学成熟,到90天时升至90%,到180天时升至95%。
本研究证明了一种自动化三维超声系统由非超声检查医师在透析床边评估内瘘成熟度的可行性和准确性。